26 January 2023Big PharmaLiz Hockley

BMS sues AstraZeneca for infringing cancer treatment drug

US pharma giant says competitor’s drug Imjudo violates two patents | BMS’ blockbuster was first to use checkpoint inhibitors, says complaint.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

BMS says Hengrui’s Abraxane infringes

13 May 2022 A subsidiary of Bristol-Myers Squibb has sued Chinese pharma company Jiangsu Hengrui Pharmaceuticals, alleging that the company’s planned generic of cancer medication Abraxane infringes a patent.

Generics

Gilead, BMS, Janssen facing HIV generic antitrust suit

16 December 2021 Gilead, Bristol-Myers Squibb and Janssen are facing accusations that they suppressed competition in the market for drugs used to treat the human immunodeficiency virus.

Big Pharma

Exelixis takes Cipla to court over generic cancer drug

21 March 2023 Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.

More on this story

Generics

BMS says Hengrui’s Abraxane infringes

Generics

Gilead, BMS, Janssen facing HIV generic antitrust suit

16 December 2021 Gilead, Bristol-Myers Squibb and Janssen are facing accusations that they suppressed competition in the market for drugs used to treat the human immunodeficiency virus.

Big Pharma

Exelixis takes Cipla to court over generic cancer drug

21 March 2023 Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.

More on this story

Generics

BMS says Hengrui’s Abraxane infringes

Generics

Gilead, BMS, Janssen facing HIV generic antitrust suit

16 December 2021 Gilead, Bristol-Myers Squibb and Janssen are facing accusations that they suppressed competition in the market for drugs used to treat the human immunodeficiency virus.

Big Pharma

Exelixis takes Cipla to court over generic cancer drug

21 March 2023 Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.